Loading…
ABVC
ABVC Biopharma Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 00091F304
$0.83+4.31%Price as of Aug 29, 18:44 UTC · updated once a day, after the close
Key metrics
- Market cap
- $22.12M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.1x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.30
- ROE
- -69.86%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.63
- 52-week high
- $3.40
- 52-week low
- $0.71
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -95.6% over 5Y.
today you would have $48.92▼ -95.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $2.13 | $0.59 | $1.16 | $6.25 | $33.90 | $51.00 | $43.70 | $360.00 | $360.00 | $360.00 | $1,433.12 | $2,866.24 | $2,866.24 | $1,433.12 | $25,796.18 | $71,656.05 | |
| P/S | 152.2x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RVPRetractable Technologies Inc | $0.73 | — | 0.3x | — | -4.51% | $21.85M |
| ALLRAllarity Therapeutics, Inc. | $1.41 | — | 6.4x | — | -157.09% | $22.43M |
| BNGOBionano Genomics, Inc. | $1.82 | — | 0.7x | — | -83.56% | $21.43M |
| MRKRMarker Therapeutics, Inc. | $1.37 |
About the company
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
- 16
- Fremont, United States
Company description provided by Yahoo Finance.